Shane Johnson Biography and Net Worth

SVP of InMed Pharmaceuticals

Dr. Shane Johnson’s career has focused principally on offering strategic business advisory services to companies in the biotechnology and healthcare sectors. His work has included guiding regulatory strategy, product portfolio assessment and valuations, and product development and launch strategies for companies including Biogen Idec, Amgen, and Genentech.

Shane was a Principal at Hamilton BioVentures (a Life Science venture capital firm), an Engagement Manager at L.E.K. Consulting (an international strategy consulting firm), and held operational roles in several early stage companies. For the past 4 years, Shane’s work has been focused on the cannabis and cannabinoid science space,

and he has developed a strong working knowledge of clinical opportunities in the sector. He is currently on the Board of Directors of several cannabis-related companies, and is a co-founder of one of Nevada’s leading cultivators and producers of premium cannabis products including a patented lozenge.

Shane holds a B.A. in Studio Art and a B.S. in Neuroscience (with honors) from Brown University, an M.D. from the Stanford University School of Medicine, and is a Fulbright Scholar.

How do I contact Shane Aaron Johnson?: The corporate mailing address for Dr. Johnson and other InMed Pharmaceuticals executives is , , . InMed Pharmaceuticals can also be reached via phone at 604-669-7207 and via email at [email protected]. Learn More on Shane Aaron Johnson's contact information.
Has Shane Aaron Johnson been buying or selling shares of InMed Pharmaceuticals?: Shane Aaron Johnson has not been actively trading shares of InMed Pharmaceuticals within the last three months. Most recently, on Thursday, January 6th, Shane Aaron Johnson bought 425 shares of InMed Pharmaceuticals stock. The stock was acquired at an average cost of $25.20 per share, with a total value of $10,710.00. Learn More on Shane Aaron Johnson's trading history.
Who are InMed Pharmaceuticals' active insiders?: InMed Pharmaceuticals' insider roster includes Eric Adams (CEO), Bruce Colwill (CFO), and Shane Johnson (SVP). Learn More on InMed Pharmaceuticals' active insiders.
Are insiders buying or selling shares of InMed Pharmaceuticals?: During the last twelve months, InMed Pharmaceuticals insiders bought shares 2 times. They purchased a total of 3,955 shares worth more than $29,601.00. The most recent insider tranaction occured on February, 21st when Director Andrew Hull bought 1,875 shares worth more than $14,625.00. Insiders at InMed Pharmaceuticals own 1.9% of the company. Learn More about insider trades at InMed Pharmaceuticals.
Information on this page was last updated on 2/21/2024.

Shane Aaron Johnson Insider Trading History at InMed Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
1/6/2022	Buy	425	$25.20	$10,710.00
12/30/2021	Buy	404	$26.60	$10,746.40
11/15/2021	Buy	250	$27.40	$6,850.00

Shane Aaron Johnson Buying and Selling Activity at InMed Pharmaceuticals

InMed Pharmaceuticals Company Overview

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Today's Range

Now: $3.89

$3.65

$4.29

50 Day Range

MA: $5.00

$4.04

$7.10

2 Week Range

Now: $3.89

$2.41

$15.70

Volume

23,107 shs

Average Volume

121,745 shs

Market Capitalization

$2.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

Is Your Portfolio Caught in A "Post-Election Trap"?

From Stansberry Research | Ad

Most investors don't see the problem yet... and many think this current rally could keep going for months or even years. But one of my most senior analysts has been sending this around – and it's startling.

Click here to see Dan's full warning (and his potential solution)